An "Other News To Note" item in the Dec. 28, 1998 issue of BioWorld Today should have said Guilford Pharmaceuticals Inc. will receive $2 million as a milestone payment from Rhone-Poulenc Rorer Inc., upon approval of Gliadel for marketing in Canada.